Elvinix is developing a regenerative, disease-modifying therapy designed to restore and protect the body’s own insulin-producing beta cells.
An estimated 9.5 million people live with type 1 diabetes worldwide, and that number continues to rise. For more than a century, care has advanced through insulin therapy and glucose monitoring.*
* International Diabetes Federation, IDF Diabetes Atlas, 11th edition, and T1D Index, 2025.
Elvinix is developing a regenerative, disease-modifying therapy for type 1 diabetes, designed to restore and protect the body’s own insulin-producing capacity. The approach brings together complementary mechanisms to address the disease at its source.
Our work is built on a proprietary peptide platform developed by a recognized leader in peptide-based medicines. The specifics of our molecules, target and data remain confidential as the program progresses.
Elvinix was co-founded with internationally recognized leaders whose work has shaped the understanding of beta-cell biology, the design of diabetes clinical trials, and the development of metabolic therapies for patients.
Our team combines world-class scientific, clinical, and regulatory expertise from globally recognised companies and institutions to advance a new approach to treating type 1 diabetes.
Elvinix works with investors and strategic partners who share our commitment to changing the course of type 1 diabetes.
Request a conversation
